Richard Kradin M.D.

Bio

Richard L. Kradin, M.D., is an associate pathologist and physician at Massachusetts General Hospital (MGH) in Boston and an associate professor at Harvard Medical School.

Specializing in pulmonary and critical care medicine, Kradin is interested in pulmonology and autopsy pathology. He treats dyspnea, interstitial lung diseases, kidney cancer, lung cancer and pulmonary fibrosis.

Some of his research interests include infectious disease, pulmonary immunity and asbestos-related disease. One asbestos-related condition that is a particular interest of Kradin's is mesothelioma, a rare cancer often associated with heavy but short-term asbestos exposure. The most common type is pleural mesothelioma, which develops in the lining of the lungs.

His primary focus for mesothelioma involves diagnosing and managing the disease. In a 2006 report, Kradin evaluated and acknowledged the increase in diffuse malignant mesothelioma cases, which is an unusual growth pattern for the cancer.

After finishing his education at Jefferson Medical College in 1976, Kradin completed residencies at MGH and Pennsylvania Hospital. He returned to MGH for his fellowship, where he is now director of infectious disease pathology.

Kradin is also part of the department of medicine and department of pathology at MGH. He is board certified in internal medicine, anatomic pathology and pulmonary disease.

What is Mesothelioma and how is it Treated?

Mesothelioma is a rare cancer that affects the lining of the lungs. To learn more about the disease, including its causes and how it is treated, request a free mesothelioma packet from The Mesothelioma Center. This packet provides lists of top doctors and cancer centers as well as information on financial assistance that may cover medical costs associated with a diagnosis of mesothelioma or other diseases related to asbestos exposure. Click here to have the complimentary packet delivered to you.

Publications

Both of Kradin's publications that deal with mesothelioma appear in Seminal Diagnostic Pathology: "Distinguishing Benign Mesothelial Hyperplasia from Neoplasia: A Practical Approach" and "Pathological Recognition of Diffuse Malignant Mesothelioma of the Pleura: The Significance of the Historical Perspective as Regards this Signal Tumor."